JP7432503B2 - 塩酸メフパリブの多形体およびその製造方法と使用 - Google Patents

塩酸メフパリブの多形体およびその製造方法と使用 Download PDF

Info

Publication number
JP7432503B2
JP7432503B2 JP2020519169A JP2020519169A JP7432503B2 JP 7432503 B2 JP7432503 B2 JP 7432503B2 JP 2020519169 A JP2020519169 A JP 2020519169A JP 2020519169 A JP2020519169 A JP 2020519169A JP 7432503 B2 JP7432503 B2 JP 7432503B2
Authority
JP
Japan
Prior art keywords
water
crystal form
hydrochloride
fluorobenzofuran
methylaminomethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020519169A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524707A (ja
Inventor
ヤン，チュンハオ
ミャオ，ゼホン
タン，チュン
フアン，シアフアン
ディン，ジィェン
チェン，イー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fukang Shanghai health Technology Co ltd
Shanghai Institute of Materia Medica of CAS
Original Assignee
Fukang Shanghai health Technology Co ltd
Shanghai Institute of Materia Medica of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fukang Shanghai health Technology Co ltd, Shanghai Institute of Materia Medica of CAS filed Critical Fukang Shanghai health Technology Co ltd
Publication of JP2020524707A publication Critical patent/JP2020524707A/ja
Priority to JP2021194722A priority Critical patent/JP2022060192A/ja
Application granted granted Critical
Publication of JP7432503B2 publication Critical patent/JP7432503B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2020519169A 2017-06-14 2018-05-31 塩酸メフパリブの多形体およびその製造方法と使用 Active JP7432503B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021194722A JP2022060192A (ja) 2017-06-14 2021-11-30 塩酸メフパリブの多形体およびその製造方法と使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710449281.2 2017-06-14
CN201710449281.2A CN109134409B (zh) 2017-06-14 2017-06-14 盐酸美呋哌瑞多晶型物及其制备方法与应用
PCT/CN2018/089222 WO2018228205A1 (zh) 2017-06-14 2018-05-31 盐酸美呋哌瑞多晶型物及其制备方法与应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021194722A Division JP2022060192A (ja) 2017-06-14 2021-11-30 塩酸メフパリブの多形体およびその製造方法と使用

Publications (2)

Publication Number Publication Date
JP2020524707A JP2020524707A (ja) 2020-08-20
JP7432503B2 true JP7432503B2 (ja) 2024-02-16

Family

ID=64660851

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020519169A Active JP7432503B2 (ja) 2017-06-14 2018-05-31 塩酸メフパリブの多形体およびその製造方法と使用
JP2021194722A Pending JP2022060192A (ja) 2017-06-14 2021-11-30 塩酸メフパリブの多形体およびその製造方法と使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021194722A Pending JP2022060192A (ja) 2017-06-14 2021-11-30 塩酸メフパリブの多形体およびその製造方法と使用

Country Status (11)

Country Link
US (1) US11174237B2 (enExample)
EP (1) EP3643708B1 (enExample)
JP (2) JP7432503B2 (enExample)
KR (1) KR102458566B1 (enExample)
CN (1) CN109134409B (enExample)
AU (1) AU2018286057B2 (enExample)
CA (1) CA3067336C (enExample)
SG (1) SG11201912281PA (enExample)
TW (1) TWI675027B (enExample)
WO (1) WO2018228205A1 (enExample)
ZA (1) ZA202000224B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109134409B (zh) * 2017-06-14 2023-09-29 中国科学院上海药物研究所 盐酸美呋哌瑞多晶型物及其制备方法与应用
CN111320596B (zh) * 2018-12-14 2024-07-05 甫康（上海）健康科技有限责任公司 盐酸美呋哌瑞多晶型物及其制备方法
EP4112049A4 (en) * 2020-02-24 2024-07-24 Fukang (Shanghai) Health Technology Co., Ltd. ANTI-CORONAVIRUS APPLICATION OF POLY ADP-RIBOSE POLYMERASE INHIBITOR

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015511942A (ja) 2012-02-09 2015-04-23 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズＳｈａｎｇｈａｉ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｍａｔｅｒｉａ Ｍｅｄｉｃａ， Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ Ｏｆ Ｓｃｉｅｎｃｅｓ ２−アリールベンゾフラン−７−カルボキサミド系化合物、その製造方法および用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102627620B (zh) * 2012-04-10 2015-12-16 江苏先声药物研究有限公司 一类苯并呋喃衍生物及其医药应用
CN104003979B (zh) * 2013-02-21 2016-08-17 上海汇伦生命科技有限公司 苯并咪唑-2-哌嗪类化合物、其药物组合物及其制备方法和用途
WO2015032328A1 (zh) * 2013-09-03 2015-03-12 四川海思科制药有限公司 茚满衍生物及其制备方法和在医药上的应用
CN104003940B (zh) * 2014-06-16 2017-02-15 华东理工大学 2,4‑二氟‑5‑(酞嗪酮‑1‑甲基)‑苯甲酰哌嗪类化合物及其用途
CN109134409B (zh) * 2017-06-14 2023-09-29 中国科学院上海药物研究所 盐酸美呋哌瑞多晶型物及其制备方法与应用
CN111320596B (zh) * 2018-12-14 2024-07-05 甫康（上海）健康科技有限责任公司 盐酸美呋哌瑞多晶型物及其制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015511942A (ja) 2012-02-09 2015-04-23 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズＳｈａｎｇｈａｉ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｍａｔｅｒｉａ Ｍｅｄｉｃａ， Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ Ｏｆ Ｓｃｉｅｎｃｅｓ ２−アリールベンゾフラン−７−カルボキサミド系化合物、その製造方法および用途

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ＰＨＡＲＭ ＴＥＣＨ ＪＡＰＡＮ、２００２年、Ｖｏｌ．１８、Ｎｏ．１０、ｐ．１６２９～１６４４
ＰＨＡＲＭＡＣＥＵＴＩＣＡＬ ＲＥＳＥＡＲＣＨ、１９９５年、Ｖｏｌ．１２、Ｎｏ．７、ｐ．９４５～９５４
平山令明、有機化合物結晶作製ハンドブック、２００８年、ｐ．１７～２３、３７～４０、４５～５１、５７～６５
日本化学会編、実験化学講座（続）２ 分離と精製、丸善株式会社、１９６７年、ｐ．１５９～１９４
緒方章、化学実験操作法 上巻、株式会社南江堂、１９６３年、ｐ．３６６～３９９

Also Published As

Publication number Publication date
WO2018228205A1 (zh) 2018-12-20
US20200172502A1 (en) 2020-06-04
KR20200014924A (ko) 2020-02-11
JP2020524707A (ja) 2020-08-20
KR102458566B1 (ko) 2022-10-24
EP3643708C0 (en) 2025-09-24
AU2018286057A1 (en) 2020-01-30
CA3067336A1 (en) 2018-12-20
CN109134409B (zh) 2023-09-29
US11174237B2 (en) 2021-11-16
TWI675027B (zh) 2019-10-21
ZA202000224B (en) 2021-08-25
EP3643708A4 (en) 2021-02-24
SG11201912281PA (en) 2020-01-30
AU2018286057B2 (en) 2021-03-18
EP3643708A1 (en) 2020-04-29
JP2022060192A (ja) 2022-04-14
CN109134409A (zh) 2019-01-04
CA3067336C (en) 2022-11-15
TW201904952A (zh) 2019-02-01
EP3643708B1 (en) 2025-09-24

Similar Documents

Publication Publication Date Title
JP2022060192A (ja) 塩酸メフパリブの多形体およびその製造方法と使用
ZA200407799B (en) Lansoprazole polymorphs and processes for preparation thereof
US10336835B2 (en) Polymorphs of sugammadex and process for preparation of sugammadex
AU2023223327A1 (en) POLYMORPHIC FORM OF REDUCED β-NICOTINAMIDE MONONUCLEOTIDE DISODIUM SALT, AND PREPARATION METHOD THEREFOR AND USE THEREOF
EP3830184B1 (en) Solid state forms of sugammadex sodium
WO2005051925A1 (ja) フェニルアラニン誘導体の結晶及びその製造方法
EP2118117A2 (en) Solid state forms of 5-azacytidine and processes for preparation thereof
JP2008506783A (ja) ミコフェノール酸ナトリウムの結晶形の調製方法
JP2022060192A5 (enExample)
CN111320596B (zh) 盐酸美呋哌瑞多晶型物及其制备方法
RU2783418C1 (ru) Способ получения полиморфа гидрохлорида 2-[4-(метиламинометил)фенил]-5-фтор-бензофуран-7-карбоксамида
RU2783418C9 (ru) Способ получения полиморфа гидрохлорида 2-[4-(метиламинометил)фенил]-5-фтор-бензофуран-7-карбоксамида
CN107698563B (zh) 制备马来酸来那替尼晶型的方法
WO2025094081A2 (en) Solid state forms of deutivacaftor and process thereof
CN110964017A (zh) 瑞博西尼单琥珀酸盐的多晶型物及其制备方法和用途
EP2683696A1 (en) Process for making crystalline form a of linezolid
AU2024229918A1 (en) Solid state forms of delgocitinib and process thereof
WO2025257758A1 (en) Solid state forms of navacaprant
CN104402809A (zh) 一种托拉塞米新晶型及其制备方法
WO2020086789A1 (en) New crystalline polymorphs of rigosertib sodium
WO2006099452A1 (en) Anhydrous ziprasidone mesylate and a process for its preparation

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200703

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210616

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211130

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211130

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20211208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211203

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220112

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220113

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220218

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220222

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230823

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230922

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231023

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20231108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240205

R150 Certificate of patent or registration of utility model

Ref document number: 7432503

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150